Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SIF
|
|||
| Former ID |
DNCL001567
|
|||
| Drug Name |
Milatuzumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1], [2] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 1 | [3] | ||
| Company |
Immunomedics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HLA-DR antigens-associated invariant (CD74) | Target Info | . | [4] |
| KEGG Pathway | Antigen processing and presentation | |||
| Tuberculosis | ||||
| Herpes simplex infection | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Panther Pathway | T cell activation | |||
| Reactome | MHC class II antigen presentation | |||
| WikiPathways | MHC class II antigen presentation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8267). | |||
| REF 2 | ClinicalTrials.gov (NCT01845740) Phase Ib Study of SC Milatuzumab in SLE. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.